Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-Rencofilstat in Healthy Males
NCT05737433Phase 1Completed
- Sponsor
- Hepion Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rencofilstat in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF), sponsored by Hepion Pharmaceuticals. Primary endpoint: Mass Balance Recovery After a Single Oral Dose of [14C]-Rencofilstat at 22 Days. Started Mar 2023; status: completed.
02
Drugs
rencofilstat
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05737433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737433.